A discovery does not change a life on its own

In a conversation between cardiologist Tiago Bignoto and biotechnology executive Dorian Readnour, the path from a promising hypothesis to real patient impact reveals a problem of connection — and an opportunity for clinical leaders, industry, physician communities and patients to redesign that journey.

For a physician or a family, the question is usually direct: Can this patient access the treatment?

Behind that sentence lies a far less simple chain. A scientific possibility must become credible evidence; the evidence must make sense in clinical practice; the right population must be identified; regulators and payers must recognize value; and hospitals, professionals and health systems must be ready to deliver the care.

It was in this space — between discovery and real life — that two different perspectives met. Tiago Bignoto, a cardiologist, echocardiographer and founder of The Valve Club, views innovation through the patient, research and physician education. Dorian Readnour, an executive with international experience in biotechnology and rare disease, sees the same journey through strategy, development, access and implementation.

Their conversation showed that neither world can finish the work alone. Innovation becomes stronger when scientific authority, executive capability and patient experience stop operating as separate stages and begin functioning as a system.

One question, several systems

Readnour described a common asymmetry. For the physician, there is one need: “I just want access for my patient.” Inside a company, however, that request may open several distinct pathways — a clinical trial, an expanded-access programme or commercial access after approval. Each route involves different teams, evidence, rules and timelines.

This is where good intentions can become lost between structures that do not speak the same language. A company organizes the problem by process. A physician organizes it by clinical urgency. A family experiences it as time that cannot be recovered.

For Bignoto, the most critical link in the chain appears before a product reaches the market. A hypothesis must be tested through sound trial design and evidence robust enough to guide clinical decisions. In rare diseases, inherited cardiovascular conditions or highly specific populations, that becomes harder: there are fewer patients, dispersed centres and outcomes that may take years to appear.

Industry capital, technical expertise and operational capability can accelerate that journey. But investment creates more value when it meets the perspective of those who understand the disease in practice early enough. Physicians and researchers can show whether the population can be found, whether diagnosis is consistent, whether an endpoint measures something meaningful and whether existing infrastructure can use the innovation safely.

The exchange also works in the other direction. Development and access leaders can explain which evidence will be required, which barriers vary by country and which choices make a solution viable at scale. Convergence does not happen when the physician is invited merely to validate a finished plan. It begins when science and execution help frame the problem together.

The KOL as a bridge — not an endorsement

The term key opinion leader, or KOL, is still commonly associated with conference presentations and published research. Bignoto argues for a broader role: a trusted clinical and scientific leader able to connect technology development, validation, physicians and patient care.

That role requires more than visibility. It requires scientific credibility, clear communication and the independence to challenge assumptions. A useful collaboration is not one in which an expert simply lends a name to a technology. It is one in which clinical experience improves the question, the research design and the relevance of the result.

For industry, that dialogue can expose assumptions that look coherent on paper but fail in clinical practice. For physicians, it creates a channel through which unmet needs can influence research and investment priorities. For patients, it can shorten the distance between what a protocol can measure and what actually changes a life.

This triangle — executive decision-making, clinical authority and patient experience — does not eliminate conflict. Companies must consider scale and sustainability; researchers protect the quality of evidence; physicians face the urgency of an individual case; and families may value benefits that do not fit traditional measures. Progress becomes possible when those tensions are visible early rather than appearing only at the end.

Physician communities that shorten the distance

Bignoto created The Valve Club from the conviction that knowledge should not remain confined to isolated centres. By connecting cardiologists, imaging specialists, researchers and professionals working in valvular and structural heart disease, the platform turns physician education into an infrastructure for collaboration.

Such communities can speed the circulation of evidence, compare experience across centres and identify questions that a single institution may not see. They can also translate complex research into clinical decisions without reducing science to simplified messages.

Bignoto noted that only a few decades ago, obtaining a single paper could be slow. Today, physician groups discuss data almost in real time and influence how a technology is understood and applied. Speed, however, is not a substitute for judgment. The faster information travels, the greater the responsibility to distinguish signal from enthusiasm.

Networks also connect global strategy with local reality. A programme designed at an international headquarters will encounter very different diagnostic, regulatory, reimbursement and hospital-capacity conditions. Local clinicians reveal where the pathway breaks. Executive teams connect those barriers to development and access decisions. Scientific communities allow lessons from one country to be tested — not simply copied — in another.

The heart-team model described by Bignoto offers a practical image of that integration. When different specialists, the patient and the family participate in a decision, care stops being a collection of isolated opinions and becomes a shared choice. The same principle can guide innovation at a larger scale.

Evidence that measures what matters

One of the largest challenges is time. Some therapies are designed to intervene early and prevent a loss that would become visible only many years later. Waiting ten or twenty years to demonstrate benefit may be scientifically understandable, but it is impractical for patients, researchers and developers.

Readnour argued for earlier indicators and faster ways to measure effectiveness without lowering the standard of evidence. Natural-history data, registries, biomarkers and trial designs suited to small populations can help researchers interpret change and risk.

There is also a question that comes before statistics: benefit for whom? Governments and payers may prioritize one outcome while families value another. In a progressive disease, preserving upper-limb function, independence or participation in daily life may have enormous meaning even after a more familiar measure has been lost.

The patient voice, then, is not merely an emotional element added after the data. It helps define which questions should be asked, which outcomes matter and which compromises are acceptable. Data describes the scale of a need; individual stories reveal its consequences.

When integration becomes the norm

Bignoto’s view of the future does not depend on a single technology. It depends on integration. “It is a collaborative effort where everyone speaks the same language,” he said.

In that future, physicians better understand research, development and access; scientists work closer to clinical decisions; executives listen to local signals before global strategies are fixed; and patients participate before the criteria for success have been closed.

Artificial intelligence may accelerate parts of that system. Bignoto pointed to tools capable of capturing clinical signals, including sounds from the chest, and generating diagnostic hypotheses that could help bring overlooked conditions into view. Their value is not in replacing the physician, but in increasing the ability to find the right patient earlier and combine technology with examination, history and clinical judgment.

Readnour added other requirements: earlier diagnosis, education, better measures of effectiveness and greater investment in the next generation of physicians. If knowledge remains concentrated in a small number of centres or professionals, discovery will move faster than the capacity to apply it.

The most promising future, then, is not only one of more sophisticated therapies. It is one in which the healthcare ecosystem can recognize need, produce evidence, make responsible decisions and deliver access without forcing patients to navigate institutions on their own.

At the end of the conversation, Readnour observed that she and Bignoto had approached the subject from slightly different directions, but shared similar goals, aims and hopes. That convergence is more than professional courtesy. It is the condition that allows a discovery to move beyond possibility and begin, in practice, to change lives.